Rapamycin, the prototypical inhibitor of mammalian target of rapamycin (mTOR), was discovered in soil samples from Easter Island (locally known as Rapa Nui) in the 1970s and found to have antifungal activity. Now, it is increasingly recognized that mTOR has manifold functions in mammalian cells and that it acts as a central regulator of cellular metabolism 1, 2 . As such, the mTOR pathway is a target of immunosuppressive and anti-proliferative therapies for transplantation and cancer. Recent studies have established an important role for mTOR complex 1 (mTORC1) and mTORC2 in regulating the functions of innate immune cell populations. It is now clear that the mTOR signalling network functions as an integrative rheostat that orchestrates a broad network of cellular and metabolic activities that shape immune effector responses. Depending on the type of cell, its target tissue, and its extracellular and intra cellular nutrient status, the response of an individual immune cell is tailored and optimized to its specific needs.
. As such, the mTOR pathway is a target of immunosuppressive and anti-proliferative therapies for transplantation and cancer. Recent studies have established an important role for mTOR complex 1 (mTORC1) and mTORC2 in regulating the functions of innate immune cell populations. It is now clear that the mTOR signalling network functions as an integrative rheostat that orchestrates a broad network of cellular and metabolic activities that shape immune effector responses. Depending on the type of cell, its target tissue, and its extracellular and intra cellular nutrient status, the response of an individual immune cell is tailored and optimized to its specific needs.
This Review describes the multiple roles of mTOR in monocytes, macrophages, dendritic cells (DCs), neutrophils, mast cells and innate-like natural killer (NK) cells. We discuss the stimuli and signals that activate the mTOR pathway in these cells and the specific effector functions that are controlled by mTORC1 and mTORC2. We also review the recent evidence showing that the control of cellular energy metabolism by mTOR is central to directing innate effector responses.
Activation of mTOR in myeloid cells
Activated innate immune cells dramatically change their cell morphology, migrate to new tissue sites, and produce large amounts of cytokines, chemokines and lipid mediators, such as prostaglandins and leukotrienes. Many of these metabolically demanding processes are controlled and shaped by the mTORC1-mTORC2 network after cell activation. The mTORC1-mTORC2 network in innate immune cells is activated by various extracellular signals, including growth factors, Toll-like receptor (TLR) ligands and cytokines (FIG. 1) . For example, the growth factors granulocyte-macrophage colony-stimulating factor (GM-CSF) and FMS-related tyrosine kinase 3 ligand (FLT3L) induce mTORC1 activation in DCs and neutrophils [3] [4] [5] ; TLR ligands activate mTORC1 and mTORC2 in human and mouse monocytes, macrophages and DCs 3, [6] [7] [8] [9] [10] [11] [12] , and mTORC1 in mouse neutrophils 13 ; and the cytokine interleukin-4 (IL-4) promotes mTORC1 and mTORC2 activation in mouse macrophages 14, 15 , whereas IL-15 induces mTOR activity in human and mouse NK cells 16 . Without these activating signals, the mTOR pathway is strikingly inactive in these cells in vitro, which is in contrast to resting fibroblasts and other primary cells. Activation of mTORC1 and mTORC2 controls a wide array of basic cellular processes such as translation and protein synthesis, cell growth, metabolism and anabolic processes. For example, mouse macrophages and DCs undergo a massive increase in protein synthesis, peaking Nature Reviews | Immunology A complex composed of: mammalian target of rapamycin (mTOR), mLST8 and the adaptor proteins rapamycininsensitive companion of mTOR (RICTOR) and stress-activated MAP kinase-interacting protein 1 (SIN1).
after 4 hours of lipopolysaccharide (LPS) stimulation, that is largely dependent on the phosphatidylinositol 3-kinase (PI3K)-mTORC1 pathway 17, 18 . Interestingly, this early increase in protein synthesis seems to be independent of glucose influx and glycolysis 19 . mTORC1 regulates cap-dependent and cap-independent translation of mRNAs by directly phosphorylating inhibitors of eukaryotic trans lation initiation factor 4E (eIF4E):
namely, eIF4E-binding protein 1 (4E-BP1) and 4E-BP2. mTORC1 is particularly efficient at promoting translation initiation of mRNAs containing a 5ʹ terminal oligopyrimidine tract (5ʹ TOP) or a pyrimidine-rich translational element (PRTE), which encode many ribosomal and translation-related proteins but also metabolism-related proteins 2, 20 . In addition, ribosomal protein S6 kinase 1 (S6K1; also known as RPS6KB1) and S6K2 (also known Figure 1 | The mTOR pathway in innate immune cells. In innate immune cells, the mammalian target of rapamycin (mTOR) network can be activated via multiple signals. Growth factors, Toll-like receptor (TLR) ligands or cytokines signal through their cognate receptors to activate mTOR complex 1 (mTORC1) and mTORC2. Receptor activation leads to the recruitment of class I phosphatidylinositol 3-kinases (PI3Ks) to the receptor complex by different adaptor molecules including the small GTPase RAB8A in macrophages 60 . PI3Ks generate phosphatidylinositol-3,4,5-trisphosphate (PtdInsP 3 ) as a second messenger to recruit and activate the serine/threonine kinases AKT1, AKT2 and AKT3 via phosphorylation on threonine 308 by 3-phosphoinositide-dependent protein kinase 1 (PDPK1). This process is negatively regulated by phosphatase and tensin homologue (PTEN), which dephosphorylates PtdInsP 3 (REF. 2 ). mTORC2 phosphorylates AKT on serine 473, which seems to be required for full activation and substrate specificity of AKT. In addition, mTORC2 phosphorylates protein kinase C (PKC) and serum and glucocorticoid-regulated kinase 1 (SGK1) to regulate important cellular processes such as cytoskeleton reorganization. Two main effectors of AKT are forkhead box O1 (FOXO1) and tuberous sclerosis 2 (TSC2) 1 . TSC2 forms a heterodimeric complex with TSC1 and inhibits mTORC1. However, phosphorylation of TSC2 at threonine 1462 by AKT inhibits its GTPase-activating protein (GAP) activity for the small GTPase RAS homologue enriched in brain (RHEB), which therefore remains in a GTP-bound active state and activates mTORC1 on the lysosome. In parallel to the PI3K-AKT pathway, the mitogen-activated protein kinases (MAPKs) p38α 163, 164 and COT also activate mTORC1 via MK2-and extracellular signal-regulated kinase (ERK)-mediated phosphorylation of TSC2, respectively 72, 165 . AMP-activated protein kinase (AMPK) detects a low cellular energy status by sensing AMP levels, and it inhibits mTORC1 by phosphorylating regulatory-associated protein of mTOR (RAPTOR) at serine 792 and TSC2 at serine 1387, which promotes the inhibitory function of the TSC1-TSC2 complex. mTORC1 senses amino acid sufficiency on the lysosome via the RAS-related GTP-binding protein (RAG) GTPases and the Ragulator complex, which seems to be a prerequisite for mTORC1 activation by growth factors. Moreover, low levels of glucose-6-phosphate inactivate mTORC1 by inducing binding to hexokinase 2 (HK2). Binding of the lipid metabolite phosphatidic acid (PA) to mTORC1 is also a prerequisite for mTORC1 activation. mTORC1-dependent phosphorylation of a variety of downstream effectors -such as eIF4E-binding protein 1 (4E-BP1), 4E-BP2 (not shown) and ribosomal protein S6 kinase 1 (S6K1) -promotes protein synthesis. Activating phosphorylation is indicated by orange circles labelled 'P'; inactivating phosphorylation is indicated by fading of the circles. PRAS40, proline-rich AKT1 substrate of 40 kDa; RICTOR, rapamycin-insensitive companion of mTOR; SIN1, stress-activated MAP kinase-interacting protein 1 (also known as MAPKAP1). as RPS6KB2) are two other well-characterized targets of mTORC1-mediated phosphorylation, which in turn induce the phosphory lation and activation of S6 to stimulate protein translation. Thus, one major function of mTORC1 is to stimulate global protein synthesis after innate immune cell activation, which further induces long-term reconfiguration of cellular metabolism. In line with this, a recent report showed that the adaptation of metabolism after LPS stimulation in macrophages mainly occurs through proteome remodelling at the translational level 21 .
mTOR, metabolism and innate immunity
It is now well known that T cells depend on metabolic reprogramming to mount effective responses 22 . Accumulating evidence suggests that innate immune cells also actively control metabolic processes to adapt and optimize their effector functions 23 . These various effector functions are supported by an adaptation of energy metabolism to accommodate their metabolic needs and link their metabolism to the availability of nutrients. The mTOR network is a central regulator of many core metabolic processes 1, 24 . Activation of mTORC1 usually drives an anabolic response through hypoxia-inducible factor 1α (HIF1α), peroxisome proliferator-activated receptor-γ (PPARγ), sterol regulatory element-binding proteins (SREBPs) and MYC that induces the synthesis of nucleic acids, proteins and lipids 1, 25 . In addition, it drives processes such as glycolysis and mitochondrial respiration to provide the cellular energy and building blocks for these responses (FIG. 2) . mTORC2 also enhances glyco lytic metabolism by activating AKT and promoting an inactivating phosphorylation of class IIa histone deacetylases 24, 26 . This leads to the acetylation and inactivation of forkhead box protein O1 (FOXO1) and FOXO3, which in turn activates MYC transcription. The mammalian target of rapamycin complex 1 (mTORC1) promotes glycolysis through hypoxia-inducible factor 1α (HIF1α) and MYC, which enhances glucose import by increasing the expression and surface translocation of glucose transporter 1 (GLUT1) and increasing the expression of glycolytic genes. Activation of mTORC1 promotes cholesterol and fatty acid synthesis from tricarboxylic acid (TCA) cycle intermediates through a pathway involving sterol regulatory element-binding proteins (SREBPs) and peroxisome proliferator-activated receptor-γ (PPARγ), and induces mitochondrial biogenesis through the transcription factors PPARγ co-activator 1α (PGC1α) and yin and yang 1 (YY1). Fatty acids are further metabolized to lipid mediators such as leukotrienes, prostaglandins and resolvins. Cholesterol and fatty acids are also used as building blocks for endoplasmic reticulum (ER) and Golgi synthesis, which can promote the secretion of pro-inflammatory cytokines. This is especially important in dendritic cells activated by lipopolysaccharide (not shown), which promotes ER and Golgi synthesis predominantly through AKT. mTORC1 can also have a negative effect on mitochondrial respiration by inducing the expression of type I interferon (IFN) and production of nitric oxide (NO), which subsequently promote aerobic glycolysis. mTORC2 promotes metabolic reprogramming by activating MYC and AKT, which enhance the expression of various glycolytic enzymes 24 . Lactate, the end product of aerobic glycolysis, can directly reprogramme macrophages and dendritic cells and reduce the expression of interleukin-12 (IL-12), while enhancing the production of IL-10. TNF, tumour necrosis factor; TSC, tuberous sclerosis.
Tuberous sclerosis 1 (TSC1). TSC1 forms a heterodimeric complex with TSC2. The TSC1-TSC2 complex actively inhibits mammalian target of rapamycin complex 1 (mTORC1) in unstimulated cells. Stimulation promotes AKT-dependent phosphorylation and inactivation of the complex. TSC1-TSC2 seems to be a positive regulator of mTORC2.
Pyruvate
The end product of glycolysis, which can be further metabolized to lactate in a process known as aerobic glycolysis (also known as the Warburg effect). Pyruvate can also be oxidized in the mitochondria through the tricarboxylic acid (TCA) cycle followed by oxidative phosphorylation to generate ATP.
One key organelle in which mTORC1 integrates extracellular growth factor activation with nutrient and energy sensing is the lysosome 27 . Amino acid sufficiency is sensed on the lysosomal surface by the pentameric Ragulator complex and the vacuolar ATPase. This promotes the accumulation of active hetero dimeric GTPases called RAS-related GTP-binding proteins (RAGs), which recruit mTORC1 to the lysosomal membrane. Other organelles such as the Golgi and peroxisomes have also been implicated as sites of mTORC1 activation 28, 29 . In addition to amino acids, mTORC1 can sense and integrate the AMP/ATP ratio via AMP-activated protein kinase (AMPK) 25 and the availability of glucose via glucose-6-phosphate and binding of hexokinase 2 to mTORC1 (REFS 30, 31) (FIG. 1) . Moreover, the binding of the lipid metabolite phosphatidic acid is required for mTORC1 activation on the lysosome 32 . Hence, mTORC1 can sense and integrate all of the main classes of nutrients and energy sources: amino acids, glucose, lipids and ATP. The current model proposes that mTORC1 activation by extracellular signals requires an intracellular sufficiency of nutrients and energy. In turn, mTORC1 stimulates further glucose uptake through the translation of HIF1α, enhances mitochondrial biogenesis through the activation of PPARγ co-activator 1α (PGC1α) and yin and yang 1 (YY1), and promotes lipid biosynthesis through the activation of SREBPs and PPARγ 33 (FIG. 2) . Genetic activation of mTORC1 by deletion of tuberous sclerosis 1 (Tsc1) promotes glycolysis, mitochondrial respiration and lipid synthesis in mouse DCs and haemato poietic stem cells 34, 35 . This metabolic reprogramming in TSC1-deficient DCs occurs partly via mTORC1-mediated expression of MYC, although mTORC2 and AKT are inhibited in these cells 35, 36 . Nevertheless, the specific functions of mTORC1-mediated metabolic reprogramming in innate immune cells are just beginning to be explored.
TLR stimulation of mouse bone marrow-derived DCs, but not primary human myeloid DCs, induces a rapid flux of glucose-derived carbon into the tricarboxylic acid (TCA) cycle and pentose phosphate pathway (occurring 1 hour after stimulation) that is dependent on TANK-binding kinase 1 (TBK1), IκB kinase-ε (IKKε) and AKT but independent of mTORC1 and HIF1α 19, 37 . This initial increase in glycolysis supports the de novo synthesis of fatty acids that are required for the expansion of the endoplasmic reticulum and Golgi, which is necessary to stimulate the production and secretion of pro-inflammatory molecules such as IL-12, tumour necrosis factor (TNF), IL-6 and CD86 (REF. 19 ). This is followed (several hours later) by an mTOR-and HIF1α-dependent metabolic switch from oxidative phosphorylation to aerobic glycolysis in mouse DCs [38] [39] [40] [41] . This switch is due to the induction of nitric oxide (NO) and type I interferon (IFN) production. NO poisons the mitochondrial respiratory chain, necessitating an increase in aerobic glycolysis to promote DC survival 39 . In these inflammatory mouse DCs, inhibition of mTORC1 inhibits NO production, preserves mito chondrial respiration and extends cell survival 40 . As human DCs usually produce only low levels of NO, at least in vitro, it is currently unclear whether these results can be extrapolated to human DC biology. Autocrine type I IFN production by mouse splenic DCs activated with polyinosinic-polycytidylic acid (poly(I:C)) also induces the switch from mitochondrial respiration to aerobic glycolysis via activation of HIF1α 41 . As the synthesis of NO by inducible NO synthase (iNOS) is HIF1α dependent 42 , type I IFN and NO may both promote the switch to aerobic glycolysis via the activation of the hypoxia sensor HIF1α. As mTORC1 positively controls type I IFN production (see below), mTORC1 regulates metabolic reprogramming in DCs at least via type I IFN and NO production. mTORC1-mediated reprogramming from oxidative phosphorylation towards aerobic glycolysis represents the metabolic basis of an effect known as trained immunity. Trained immunity refers to the nonspecific protection against secondary infections that is mediated by epigenetic reprogramming of myeloid immune cells to allow a faster and more pronounced secondary immune response 43 . Low doses of the cell wall component β-glucan of Candida albicans activate an AKTmTORC1-HIF1α-dependent glycolytic response in human monocytes, and this response is essential for the exacerbated IL-6 and TNF expression that occurs following restimulation of the monocytes with TLR ligands after 7 days 44 . Deletion of Hif1a in myeloid cells in mice impairs the protective effect of β-glucan priming on survival following a lethal Staphylococcus aureus infection 44 . By contrast, vitamin D3-induced tolerance in human DCs also requires activation of mTORC1 and aerobic glycolysis 45 . Interestingly, mTORC1-dependent induction of glycolysis is also important for activation of the NOD-, LRR-and pyrin domain-containing protein 3 (NLRP3) inflammasome and maturation of pro-IL-1β in peritoneal macrophages 46 . Finally, mTORC1-mediated metabolic reprogramming via HIF1α is essential for the proliferation and cytotoxicity in mouse NK cells (see below) 47 . In conclusion, current evidence suggests that mTORC1 primes metabolic reprogramming to enhance glycolysis via non-mutually-exclusive mechanisms in innate immune cells. This can lead to seemingly opposing functional outputs: either enhanced restimulation potential or tolerance induction; the reasons for these differences are currently unclear. It is important to note that constitutive activation of mTORC1 by deletion of Tsc1 also enhances mitochondrial respiration and lipid synthesis in DCs 35 . Therefore, although an increase in mTORC1 activity promotes glyco lysis, the pyruvate generated through this pathway can be used for aerobic glycolysis as well as mitochondrial respiration. It will be important to further link the metabolic mechanisms controlled by the mTOR network to distinct effector responses. .
Langerhans cells
A specialized subset of dendritic cells that seed the epidermal layer of the skin.
Genetic activation of PI3K and mTORC1 by deletion of phosphatase and tensin homologue (Pten) in mouse DCs causes a expansion of CD8α + DC and CD103 + DC populations in response to rapamycin 4 . However, compared to control patients, patients who have undergone renal transplantation followed by treatment with the mTOR inhibitor rapamycin have similar numbers of myeloid DCs and pDCs in their blood, suggesting that the doses of rapamycin used in the patients do not compromise the DC compartment in humans in vivo 3, 49 . Deletion of the gene encoding late endosomal/lysosomal adaptor, MAPK and mTOR activator 2 (LAMTOR2; also known as p14) in DCs activates mTORC1 and results in a marked expansion of conventional CD8α + DCs and pDCs in ageing mice 50 . LAMTOR2 is a component of the Ragulator complex and is thought to be essential for amino acid-dependent activation of mTORC1 on lyso somes. However, LAMTOR2 also regulates endosomal biogenesis and therefore decreases FLT3 turnover, leading to increased levels of surface FLT3 and increased responsiveness to FLT3L in LAMTOR2-deficient mouse DCs 50 . This in turn indirectly activates mTORC1 and promotes the expansion of DCs. By contrast, deletion of Tsc1 activates mTORC1 but impairs DC development in vitro and in vivo, and is associated with defective cell survival and proliferation 35 . Indeed, constitutive activation of mTORC1 might be detrimental, as it promotes the generation of reactive oxygen species (ROS) owing to enhanced mitochondrial biogenesis 34 . Moreover, deletion of Tsc1 is associated with diminished phosphorylation of AKT, which usually promotes the survival of various cell types 15, 34 . DC-specific loss of mTORC1, but not of mTORC2, leads to a progressive decrease in the number of Langerhans cells in the skin of mice 51 . mTORC1-deficient Langerhans cells have an increased tendency to leave the skin and show increased apoptosis, suggesting that mTORC1 is crucial for the preservation of the Langerhans cell network in mice. Mice with a deletion of Lamtor2 in CD11c + DCs display an almost complete loss of Langerhans cells in the epidermis early after birth due to impaired proliferation and increased apoptosis 52 . Overall, these results indicate that a precisely controlled activation of mTORC1 is crucial for myeloid cell development, whereas constitutive activation of mTORC1 disturbs cell homeostasis.
mTOR-mediated regulation of cytokine production. Treatment of human monocytes or primary myeloid DCs with rapamycin or ATP-competitive mTOR inhibitors
enhances their production of IL-12p40 and IL-12p70 after stimulation with TLR ligands 3, 8, 9, 11, 53, 54 . Mycobacteria-or LPS-induced production of IL-23 by human monocyte-derived macrophages and monocytes is also enhanced by rapamycin 8, 55 . An immunostimulatory effect of mTOR inhibitors is also seen in human transplant recipients in vivo 9, 56, 57 . Two human studies showed activation of IL-12-induced signalling and increased inflammatory responses by blood leukocytes from rapamycin-treated transplant recipients 56, 57 . Inhibition of the mTOR pathway with rapamycin can also have immunostimulatory effects in mouse cells and models after bacterial infections 8, 18, 58 . Inactivation of mTORC1 by genetic deletion of Rptor
Box 1 | Mechanism of action and clinical use of mTOR inhibitors
The prototypic mammalian target of rapamycin (mTOR) inhibitor rapamycin inhibits mTOR complex 1 (mTORC1) by associating with FK506-binding protein 12 (FKBP12), which then directly binds to mTORC1 (REF. 2) (see the figure). mTORC1 recruits substrates through regulatory-associated protein of mTOR (RAPTOR) that are then further aligned to the catalytic cleft of mTOR. Modelling of the rapamycin-FKBP12 complex bound to mTOR suggests that rapamycin does not inhibit initial substrate recruitment but blocks correct alignment of some substrates to the catalytic cleft 2 . This could explain why rapamycin is more effective in blocking the phosphorylation and activation of ribosomal protein S6 kinase 1 (S6K1) than that of eIF4E-binding protein 1 (4E-BP1). In addition, treatment of some cell types and mice with rapamycin can variably inhibit mTORC2 through a mechanism that is currently unknown (indicated by the dashed inhibitory lines in the figure) 156 . Rapamycin was approved in 1999 by the US Food and Drug Administration (FDA) for use in the prevention of kidney allograft rejection. Rapamycin and its derivative everolimus (earlier code name RAD001) are currently used as immunosuppressive therapies in solid organ transplantation 157 . Pro-inflammatory side effects and dyslipidaemia are frequently observed in these patients 157 . Rapamycin-eluting stents are used in patients with coronary artery lesions to prevent the recurrence of stenosis after percutaneous coronary revascularization 158 . Clinical anticancer effects of mTORC1 inhibitors are mainly restricted to advanced renal carcinoma, advanced breast carcinomas that are positive for oestrogen receptor or that are negative for HER2 (also known as ERBB2), giant cell astrocytoma and neuroendocrine pancreatic tumours 159 . The limited success of rapamycin in cancer therapy, and the recognition that classical mTOR inhibitors do not inhibit some mTORC1 substrates and are largely ineffective against mTORC2, prompted the development of the ATP-competitive catalytic mTOR inhibitor Torin 1, which inhibits mTORC1 and mTORC2. Novel catalytic mTORC1 and mTORC2 inhibitors, such as PP242 or AZD8055, have improved anticancer activity in vitro and in vivo, and some candidates have entered clinical trials 159 . Their clinical efficacy remains to be determined. Nature Reviews | Immunology (which encodes regulatory-associated protein of mTOR (RAPTOR)) in mouse intestinal DCs induces a severe inflammatory response to enteric bacteria following treatment with dextran sodium sulfate (DSS) 59 . Genetic inactivation of PI3K and pharmacological inhibition of mTORC1 promotes IL-12 production by mouse immune cells 6, 8, 58, 60 , although this seems to be more cell-type dependent than mTORC1-mediated enhancement of IL-12 expression by primary human immune cells. Accordingly, deletion of Tsc1 reduces IL-12 production by mouse bone marrow-derived DCs but promotes IL-12 production by mouse macro phages via activation of JUN N-terminal kinase 1 (JNK1; also known as MAPK8) and/or JNK2 (also known as MAPK9) 14, 35, 36, 61 . Interestingly, rapa mycin treatment or genetic deletion of Mtor does not prevent (and in fact increases) IL-12 production by TSC1-deficient macrophages 14 , suggesting that some TSC1-mediated effects are independent of mTORC1 and that some of the effects of mTOR inhibitors are mediated by inhibition of mTORC2
. Indeed, deletion of the gene encoding the mTORC2 component RICTOR enhances IL-12 production by macrophages and DCs [62] [63] [64] , potentially through the inactivation of an AKT-dependent inflammatory feedback pathway. After LPS stimulation, mTORC2 directly phosphorylates AKT, which phosphorylates and limits the activation of the proinflammatory transcription factor FOXO1 (REF. 62 ). Hence, deletion of mTORC2 activates FOXO1, which augments inflammatory gene expression and IL-12 production 62, 65 . Inactivation of TSC1 and TSC2 could therefore promote inflammatory responses by inhibiting mTORC2, which in turn activates FOXO1.
The immunostimulatory effects of mTOR inhibition can be explained by enhanced activation of nuclear factor-κB (NF-κB) and inhibition of signal transducer and activator of transcription 3 (STAT3) and glycogen synthase kinase 3β (GSK3β) 8, 54, 57 (FIG. 3a) .
At the same time, pharmacological or genetic inhibition of mTORC1 strongly reduces the expression of the anti-inflammatory cytokine IL-10 by human and mouse monocytes and DCs 3, 7, 8, 11, 53, 59, 66, 67 . This occurs through mTORC1-stimulated degradation of programmed cell death protein 4 (PDCD4), which releases Twist-related protein 2 (TWIST2) that subsequently activates IL10 expression through the transcription factor macrophage-activating factor (MAF) 68 ( FIG. 3a) . Rapamycin prevents the LPS-induced degradation of PDCD4 and suppresses IL-10 production by mouse macrophages. Overall, these data show that inhibition of mTORC1 or mTORC2 generally has an immunostimulatory effect in TLR-stimulated primary myeloid immune cells.
Inhibition of mTORC1 in in vitro-generated human monocyte-derived DCs (moDCs) during LPS stimulation usually has no immunostimulatory effect 3 . Rapamycin does not augment NF-κB signalling in these cells and instead inhibits expression of IL-12p40, TNF and IL-6. Interestingly, mTORC1 is constitutively active in human moDCs but not in human myeloid DCs 3, 69 ; however, the molecular basis for these discrepancies is currently unclear
. Moreover, in vitro differentiation of moDCs with GM-CSF and IL-4 in the continuous presence of rapamycin induces their conversion into tolerogenic DCs 49, 70, 71 . These tolerogenic DCs are characterized by an immature phenotype and low expression of pro-inflammatory cytokines and T cell-stimulatory molecules 70 . In contrast to human DCs, rapamycin-conditioned mouse tolerogenic DCs are resistant to LPS-or cytokinemediated maturation and T cell stimulation 70 , which has been harnessed for experimental cell-based tolerogenic therapies (see below).
Activating mTORC1-dependent translation can bias mouse macrophages towards anti-inflammatory cytokine expression: low-abundance mRNAs such as Il10 are more strongly expressed than high-abundance pro-inflammatory cytokine mRNAs 18 . This is important in the defence against a virulent strain of Legionella pneumophila, which induces ubiquitylation and inactivation of mTOR and AKT in macrophages, stimulating a pro-inflammatory cytokine response and bacterial clearance 18 . Hence, blocking mTOR with rapamycin favours the translation of the more abundant proinflammatory cytokines. By contrast, the protooncogene cancer Osaka thyroid oncogene (COT; also known as MAP3K8 and TPL2) positively controls capdependent mRNA translation of Tnf and Il6 through mTORC1 in TLR-stimulated mouse macrophages 72 . Nevertheless, translational control of mRNA expression can dampen the pro-inflammatory response 73 . Stimulation of mouse macrophages with LPS activates the translation of many mRNAs that encode feedback inhibitors -such as NF-κB inhibitors and dual specificity protein phosphatase 1 (DUSP1) -to limit an excessive inflammatory and self-destructive response 73 . A potential role of mTORC1 in regulating the translation of these inhibitors has not been investigated but might explain some of the immunostimulatory effects of mTORC1 inhibition.
Translational control is also important for the regulation of type I IFN production by myeloid DCs and pDCs. Efficient translation of the transcription factor IFN-regulatory factor 7 (IRF7), which stimulates IFNα and IFNβ production in pDCs, is induced by the mTORC1-dependent phosphorylation and inactivation of the translational inhibitors 4E-BPs 74 (FIG. 3b) .
Of note, mouse and human pDCs show constitutive expression of IRF7 in contrast to other DCs, and this correlates with a constitutively active mTORC1 pathway in these cells 75 . The Leishmania major protease GP63 directly cleaves mTOR and maintains translational repression by 4E-BP1 (REF. 76 ). This suppresses the translation of mRNAs encoding type I IFNs and microbicidal proteins, and confers an intracellular survival advantage for L. major 76 . Moreover, S6K1 and S6K2 phosphorylate and induce the nuclear translocation of IRF7, which together with IRF5, stimulates type I IFN production 10, 75, 77 (FIG. 3b) . Therefore, the mTORC1 downstream effectors 4E-BPs and S6Ks positively control the translation and activation of IRF7 and thus type I IFN expression. Nature Reviews | Immunology and mTORC2. The AKT-mTORC1 network positively regulates IL-10 expression by at least three non-mutually exclusive mechanisms. mTORC1 induces the phosphorylation (indicated by orange circle labelled 'P') of signal transducer and activator of transcription 3 (STAT3) via currently unknown kinases. mTOR or ribosomal protein S6 kinase 1 (S6K1) phosphorylate programmed cell death protein 4 (PDCD4), which subsequently gets degraded by the proteasome. The transcription factor Twist-related protein 2 (TWIST2) is released from PDCD4 and translocates to the nucleus to induce the expression of MAF. In addition, AKT phosphorylates and inhibits glycogen synthase kinase 3 (GSK3), which is then unable to phosphorylate and inhibit the transcriptional activity of cAMP response element-binding protein (CREB). Hence, mTORC1 promotes the expression of IL-10 via STAT3, MAF and CREB. mTORC1 decreases the activation of nuclear factor-κB (NF-κB) and the expression of IL-12. In addition, mTORC2 negatively regulates IL-12 production by inducing an AKT-dependent inactivation of forkhead box O1 (FOXO1), which usually promotes NF-κB activation. b | The expression of type I interferons (IFNs) by dendritic cells (DCs) is regulated by S6K1, S6K2 and eukaryotic translation initiation factor 4E (eIF4E)-binding proteins (4E-BPs) downstream of mTORC1. Phosphorylation of 4E-BP1 and 4E-BP2 by mTORC1 releases eIF4E, which promotes the translation of IFN-regulatory factor 7 (IRF7). In addition, S6K1 and S6K2 phosphorylate IRF7 to activate IFNα and IFNβ production, which is supported by IRF5. c | Lipopolysaccharide (LPS) activates mTORC1 and inhibits the transcription of new MHC class II mRNAs mediated by IRF4 and class II co-activator (CIITA). mTORC1 activation also limits antigen processing by decreasing autophagy, which contributes to the presentation of endogenous and exogenous antigen loading on MHC class I and class II molecules. mTORC1 promotes the expression of programmed cell death ligand 1 (PDL1), which limits T cell activation. mTORC1 positively regulates the production of CC-chemokine ligand 2 (CCL2) and negatively regulates signalling by CC-chemokine receptor 7 (CCR7), thereby affecting the migration of DCs to tissues and secondary lymphoid organs. Poly(I:C), polyinosinic-polycytidylic acid; TSC, tuberous sclerosis.
M1 and M2 macrophage subsets
Macrophages display considerable plasticity and can change their function in response to local environmental stimuli. M1 (or classically activated) macrophages mediate defence against various pathogens and tumours and contribute to chronic inflammatory diseases and autoimmunity. M2 (or alternatively activated) macrophages are required for defence against parasitic infections, to promote the resolution of inflammation, and to initiate tissue repair, and they are also implicated in promoting tumour growth.
STAT6
(Signal transducer and activator of transcription 6). A transcription factor that is important for M2 macrophage polarization after stimulation with interleukin-4 (IL-4) or IL-13. STAT6 regulates many M2 macrophage-associated genes, such as those encoding arginase 1, CD206, resistin-like-α and chitinase-like protein 3 (also known as YM1).
mTOR-mediated control of macrophage polarization.
Macrophage function depends on proper activation and polarization into distinct subtypes with individual effector functions, such as the M1 and M2 macrophage subsets (for a discussion, see REF. 78 ). Macrophage polarization is thought to be regulated not only by cytokines and growth factors but also by environmental cues, such as the presence of nutrients, fatty acids and other metabolites 79, 80 . Therefore, it is not surprising that PI3K-AKT-mTOR-mediated sensing of environmental and metabolic cues influences macrophage polarization in a complex and incompletely understood manner (TABLE 1) .
Mouse macrophages with constitutively enhanced PI3K and mTOR signalling caused by myeloid cellspecific deletion of Pten or Inpp5d (which encodes inositol polyphosphate-5-phosphatase D (also known as SHIP)) express higher levels of M2 macrophage markers and have enhanced activation of the STAT6 signalling pathway [81] [82] [83] . Inhibition of mTORC1 with rapamycin in human macrophages enhances M1 macrophage polarization 67, 84 . These results indicate that activation of the PI3K-mTOR network promotes M2 macrophage polarization 6, 8, 59, 85 . However, increased mTORC1 activity and reduced mTORC2 activity by ablation of Tsc1 promotes M1 macrophage polarization and reduces M2 macrophage polarization 14, 15 . This seems to be mediated by different pathways that are independent of STAT6 and PPARγ, two well-known M2 macrophage-promoting proteins. Tsc1 deletion promotes M1 macrophage polarization by activating a RAS GTPase-RAF1-MAPK/ERK kinase (MEK)-ERK pathway that is independent of mTORC1 (REF. 14). In addition, deletion of Tsc1 reduces the expression of CCAAT enhancer-binding protein-β (CEBPβ) and reduces M2 macrophage polarization by activation of mTORC1 (REF. 14) . By contrast, another group found that deletion of Tsc1 in macrophages enhances M2 as well as M1 macrophage polarization 86 . Inhibition of mTORC1 by deletion of Rptor in myeloid cells protects against inflammation in an obesity model and seems to enhance M2 macrophage polarization 87 . Moreover, a positive signal of TSC1 to AKT can also drive M2 macrophage polarization 15 . However, the role of AKT is not straightforward, as the AKT isoforms differentially control macrophage polarization 88 . Ablation of Akt1 gives rise to M1 macrophages, and deletion of Akt2 promotes a M2 macrophage phenotype in in vivo models of colitis and atherosclerosis 88, 89 . Akt2-knockout macrophages show enhanced expression of CEBPβ 88 . Macrophage-specific genetic deletion of the kinase 3-phosphoinositide-dependent protein kinase 1 (Pdpk1), which is crucial for AKT activation (FIG. 1) , increases M1 macrophage polarization and promotes insulin resistance 90 . In line with this, deletion of the gene encoding AMPK β1-subunit reduces AKT activation and promotes M1 macrophage polarization 91, 92 . Finally, mice with a myeloid cell-specific Rictor deletion show stronger M1 macrophage polarization potential and reduced M2 macro phage polarization potential 63 . Overall, these results indicate that macrophage polarization is controlled by the PI3K-AKT-mTOR pathway; however, a complete understanding of the functional roles of the individual pathway members requires further research
.
There is initial evidence that macrophage polarization might also be regulated by metabolic reprogramming 93 .
In that regard, activation of pyruvate dehydrogenase kinase 1 (PDK1), a positive regulatory enzyme in glucose metabolism, promotes mouse M1 macrophage polarization 94 . Surprisingly, MYC, a stimulator of aerobic glycolysis, is highly expressed in M2 macrophages and is crucial for M2 macrophage polarization by inducing approximately half of the genes associated with alternative activation 95 . It is interesting that lactic acid -an end product of aerobic glycolysis -primes M2-like macrophage polarization in mouse macrophages and inhibits IL-12 production but enhances IL-10 production by human monocyte-derived DCs 96, 97 . Hence, one can envision that strongly glycolytic M1 macrophages prime for subsequent M2 macrophage responses. Indeed, the presence of M1 macrophages is a prerequisite for the successive emergence of M2 macrophages and tissue homeostasis during wound healing or Listeria mono cytogenes infections 98, 99 . Moreover, these results, together with the notion that the AMPK-AKT-mTOR network is a global sensor of nutrients and energy, support the need for caution with regard to cell density and cell culture composition in in vitro experiments when analysing macrophage polarization or innate immune cell activation. Whether the mTOR network mediates macrophage polarization via metabolic reprogramming is currently unclear but warrants further investigation.
Box 2 | Pro-inflammatory versus anti-inflammatory effects of mTOR
There are seemingly contrasting roles of mammalian target of rapamycin (mTOR) in individual cells or models, which mirror contradictory data from the phosphatidylinositol 3-kinase (PI3K) pathway 160 . These observations might be a consequence of different experimental conditions, such as the analysis of primary versus in vitro-generated cells or cell lines. Alternatively, species-specific differences between mice and humans in the importance of the arginine and nitric oxide system, which is regulated by PI3K-mTOR, might explain these results. Importantly, the choice of cytokines for analysis can also influence the overall interpretation of the data. Inhibition of mTOR usually promotes interleukin-12 (IL-12) expression and blocks IL-10 expression, suggesting a pro-inflammatory (or immunostimulatory) role for mTOR inhibitors. However, tumour necrosis factor (TNF) and IL-6 are often blocked by rapamycin, leading to the conclusion that mTOR inhibitors are anti-inflammatory. The complexity of the pathway itself could also account for differential outputs. For example, inhibition of mTORC1 activates the PI3K-AKT pathway through a feedback loop via ribosomal protein S6 kinase 1 (S6K1). AKT functions upstream of mTORC1 and downstream of mTORC2. Individual AKT isoforms promote distinct macrophage polarization states, and AKT phosphorylation status changes substrate specificity 161 . Tuberous sclerosis 1 (TSC1) and TSC2 have distinct and not completely overlapping functions that are not always mTOR dependent 162 . Constitutive activation of the mTOR network by deletion of the genes encoding TSC1 or TSC2 may change manifold biological processes that differ from the short-term activation that occurs after Toll-like receptor stimulation, for example. TSC1 or TSC2 deficiency consistently reduces activation of mTORC2 and AKT (following serine 473 phosphorylation), which provide feedback to dampen forkhead box O1 (FOXO1)-induced innate immune activation. Incomplete inhibition of mTOR complex 1 (mTORC1) and mostly undefined inhibition of mTORC2 by classical mTOR inhibitors complicate the interpretation of results using inhibitors. Moreover, depending on the in vivo model used, the relative importance of the mTOR network for cell migration and chemotaxis versus cell-intrinsic immunomodulation will dictate the 'inflammatory' outcome. These observations suggest that the PI3K-AKTmTOR network is not a simple linear pathway that transmits a single signal when activated but integrates diverse intracellular and extracellular cues to regulate a diverse set of basic biological processes within the cell to adapt a given effector response to the environment. MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; NF-κB, nuclear factor-κB; OVA, ovalbumin; PDPK1, 3-phosphoinositide-dependent protein kinase 1; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homologue; RAPTOR, regulatory associated protein of mTOR; RICTOR, rapamycin-insensitive companion of mTOR; SOCS3, suppressor of cytokine signalling 3; STAT6, signal transducer and activator of transcription 6; TSC, tuberous sclerosis.
mTOR-mediated regulation of autophagy. The starvation-induced degradation of cytosolic components known as autophagy is crucial in providing substrates for energy production under catabolic conditions of limited nutrient supply. It is important to note that autophagy in macrophages is not a strictly catabolic process but is actively engaged after macrophage activation by a TLR-TNF receptor-associated factor 6 (TRAF6)-beclin 1-dependent pathway to promote basic effector functions 100 . Autophagy supports the elimination of intracellular pathogens and phagocytosed materials, and facilitates the synthesis of secretory proteins, such as IL-6 and IL-8, by providing amino acids [100] [101] [102] . mTOR and AMPK control the serine/threonine kinases ULK1 and ULK2, which are an additional system that controls autophagosome formation and autophagic flux 100 . mTORC1 actively suppresses autophagy by phosphorylating ULK1 and, accordingly, inhibition of mTORC1 strongly induces autophagy 100 . However, termination of autophagy and reformation of lyso somes requires reactivation of mTORC1 (REF. 103 ). Autophagy regulation by mTORC1 in mouse macro phages is an important defence mechanism against Mycobacterium tuberculosis, Salmonella enterica subsp. enterica serovar Typhimurium and Pseudomonas aeruginosa, and it limits their intracellular growth [104] [105] [106] [107] . Mycobacterial infection enhances the expression of the microRNA miR-155, which inhibits the expression of the small GTPase RAS homologue enriched in brain (RHEB) by binding to the 3ʹ untranslated region of Rheb mRNA 105 . This leads to mTORC1 inhibition, activation of autophagy and enhanced intracellular killing of the mycobacteria in vitro and in vivo 105 . S. Typhimurium encodes genes on the Salmonella pathogenicity island 2 that activate focal adhesion kinase (FAK). This leads to enhanced AKT and mTOR signalling, which inhibits autophagy and promotes intracellular pathogen survival in mouse macrophages 108 . To evade immune-mediated control, HIV-1 induces a shutdown of autophagy after infection of human DCs by activating mTOR 109 . Defects in macrophage autophagy are linked to the progression of atherosclerosis through effects on cholesterol homeostasis, oxidative stress and inflammation 110 . Autophagy promotes the degradation and clearance of ingested complex lipids such as low-density lipoprotein (LDL) cholesterol. Accordingly, activation of mTOR enhances the accumulation of lipids and foam cell formation owing to inhibition of autophagy, whereas genetic or pharmacological inhibition of mTORC1 reduces atherosclerotic disease, macrophage plaque infiltration and systemic inflammation in various animal models [111] [112] [113] [114] . These results suggest that mTORC1 inhibition could be an approach to treat atherosclerosis. mTOR in antigen presentation and T cell stimulation. mTORC1 is intimately involved in antigen presentation by DCs and thereby able to modulate their T cellstimulatory capacity. As autophagy contributes to the presentation of endogenous and exogenous proteins on MHC class I and class II molecules 115 , it follows that autophagy induction by mTOR inhibitors enhances antigen presentation 116 (FIG. 3c) . However, endo cytosis of mouse splenic DCs is decreased in rapamycin-treated mice in vivo 117 . Analysis of human transplant recipients shows that the antigen processing pathway is positively regulated in those treated with rapamycin, predominantly as a result of the drug triggering antigen presentation 56 . Accordingly, chronic activation of mTORC1 by deletion of Tsc1 strongly reduces MHC class II expression by mouse DCs 61 . In resting wild-type DCs, mTORC1 activity is low, allowing expression of the class II coactivator (CIITA), which stimulates MHC class II mRNA transcription. LPS stimulation or Tsc1 deletion activates mTORC1 and rapidly shuts off Ciita transcription. Thereby, the further transcription of new MHC class II molecules is prevented, allowing for efficient cell surface expression of existing peptide-MHC class II complexes 61 . Inhibition of mTOR promotes the expression of the T cell co-stimulatory molecule CD86, whereas expression of the T cell-inhibitory molecule programmed cell death ligand 1 (PDL1) is decreased 3, 8, 37, 59 (FIG. 3c) .
Moreover, inhibition of mTORC1 enhances the lifespan of LPS-stimulated mouse DCs, increasing the time available to drive T cell activation 37, 40 . This evidence, together with its potential to skew cells towards IL-12 production, predicts that inhibition of mTORC1 in DCs promotes T cell activation. Indeed, inhibition of mTORC1 in human or mouse DCs during TLR stimulation augments the proliferation of CD4 + T helper 1 (T H 1) and T H 17 cells in vitro [7] [8] [9] 37, 53 . Similarly, mTORC2 deficiency in mouse DCs also enhances T H 1 and T H 17 cell responses 64 . Mice immunized with rapamycin-treated DCs and the tuberculosis-vaccine strain bacille Calmette-Guérin (BCG) show enhanced T H 1 cell-mediated protection against virulent M. tuberculosis 116 . Therapeutic vaccination using DCs treated with TLR agonists plus rapamycin results in improved generation of CD8 + T cells and improved antitumour immunity in a mouse melanoma model 37 . Treatment of mice with an immunostimulatory agonistic CD40-specific antibody, together with AZD8055, an ATP-competitive mTOR inhibitor, elicits synergistic antitumour responses in a metastatic renal cell carcinoma model 12 . Accordingly, constitutive activation of mTORC1 in DCs by deletion of Tsc1 inhibits T cell responses in vivo 35, 61 . Finally, rapamycin-treated transplant recipients show increased frequencies of alloreactive T cells compared with control patients 56 . These potent immunostimulatory effects of rapamycin in DCs have to be considered in the context of the immunosuppressive and immuno modulatory effects on T cells at a systemic level 118 . Nevertheless, it might be possible to design novel human vaccination strategies, in which local administration of mTOR inhibitors together with an antigen-adjuvant complex or with antigen-loaded DCs might allow for an improved immune response.
However, a seemingly different outcome with rapamycin can also be generated: as noted above, the differentiation of moDCs in vitro in the presence of rapamycin generates tolerogenic DCs that inhibit effector T cell activation but maintain the ability to stimulate regulatory T cells 71 . Tolerogenic DCs generated in the presence of the catalytic mTOR inhibitor Torin 1
also promote the differentiation of regulatory T cells 119 . Injection of such tolerogenic rapamycin-conditioned DCs into mice can prolong graft survival in various transplantation models 70, 120 . mTOR in innate immune cell migration. mTOR signalling has contrasting effects on innate immune cell migration. On the one hand, mTORC1 inhibition enhances the expression of CC-chemokine receptor 7 (CCR7) by human monocytes and DCs 67, 121 , as well as T cells 122 , and thereby promotes the migration of DCs and mouse Langerhans cells 51, 121 to secondary lymphoid organs and the induction of adaptive immune responses (FIG. 3c) . On the other hand, mTORC1 inhibition reduces CC-chemokine ligand 2 (CCL2) secretion by human and mouse monocytes, macrophages and DCs, and thereby reduces chemotactic activity of monocytes and basophils 8, 113, 114, 123 . This effect of mTORC1 inhibition has been shown to be beneficial in mouse and rabbit models of atherosclerosis 113, 123 . By contrast, AKT-dependent activation of mTORC1 induces a translational switch from the transcription factor isoform CEBPβ liver-enriched activator protein (LAP) to the dominant-negative isoform CEBPβ liverenriched inhibitory protein (LIP) after activation of the bile acid-responsive G protein-coupled receptor TGR5 in mouse macrophages 124 . This diminishes the expression of the chemokines CCL2, CCL3 and CCL4 that have CEBPβ-binding sites and the migratory properties of TGR5-activated macrophages 124 . Adherence of mouse peritoneal macrophages rapidly induces the mTORC1-dependent de novo translation of pre-existing mRNAs encoding RHO-associated kinase 1 (ROCK1), which promotes macrophage chemotaxis 125 . Therefore, the current evidence suggests that mTORC1 inhibition enhances the migration of DCs, whereas it usually inhibits the migratory properties of macrophages.
mTOR in granulocytes
Neutrophil granulocytes are a first line of defence during infections, inflammation and tissue injury. They are rapidly recruited by chemotaxis and migrate to the site of infection to kill pathogens by phagocytosis, degranulation and neutrophil extracellular trap (NET) formation 126 . Chemotactic migration is controlled by mTORC2 downstream of G protein-coupled receptors in a dual manner 127 (FIG. 4a) . mTORC2 regulates actin cytoskeleton organization at the leading edge of migrating cells, and cells that lack the mTORC2 component RICTOR exhibit defects in cell polarity and chemo taxis 128, 129 . Small RHO GTPases and AKT2 function as downstream effectors of mTORC2 to regulate actin assembly at the leading edge in human and mouse neutro phils 128, 130 . In addition, mTORC2 is crucial for tail retraction in human neutrophils via the regulation of myosin II 129 . mTORC2 phosphorylates protein kinase CβII (PKCβII), which activates adenylyl cyclase 9 to convert ATP into cAMP 129, 131 . cAMP activates RHOA to further induce myosin II phosphorylation and tail retraction 129, 131 . Interestingly, rapamycin inhibits human neutrophil migration very efficiently, indicating that mTORC1 might also have a direct role in cell migration 132, 133 . Indeed, mTORC1 controls F-actin reorganization through S6K1 as well as focal adhesion formation and RHO GTPase activity in other cell types 127 . The translation of constitutively present mRNAs by mTORC1 emerges as an important mechanism by which neutrophils rapidly react to inflammatory insults [134] [135] [136] (FIG. 4b) . For example, mTORC1 controls the trans lation of pre-existing mRNA encoding cyclooxygenase 2 in human neutrophils to induce the rapid expression of prostaglandins that promote inflammation and vasodilation to attract further immune cells 134 . The soluble IL-6 receptor-α (sIL-6Rα) is synthesized in an mTORC1-dependent manner without the requirement for de novo transcription 136 . sIL-6Rα subsequently signals to endothelial cells and induces a switch from neutrophil recruitment to mononuclear leukocyte recruitment to initiate the resolution of acute inflammation 137 . Therefore, inhibition of mTORC1 in neutrophils is anti-inflammatory in early phases of inflammation, but it can prolong the acute inflammatory phase at later stages. Inhibition of mTOR by rapamycin can differentially regulate NET formation in primary human neutrophils depending on the stimulus [138] [139] [140] . Whereas rapamycin inhibits LPSinduced NET formation by translational control of HIF1α expression, it enhances formyl-methionyl-leucylphenylalanine (fMLP)-stimulated NET formation 138, 139 . The reason for these differences is currently unclear, but it may be due to differential activation of NADPH oxidases and autophagy by LPS and fMLP 138, 139, 141 . Finally, mTORC1 positively contributes to the expression of pro-inflammatory IL6, IL8 and TNF in human and mouse neutrophils via a transcriptional mechanism in vitro and in TLR4-induced lung injury in vivo 13, 142 . So far, relatively little is known about the role of mTOR in eosinophil granulocytes; however, rapamycin has been shown to inhibit the differentiation, proliferation and function of mouse eosinophils in vitro and in vivo 143 .
mTOR in mast cells
Mast cells contribute to host defence and also to allergic disorders and asthma 144 . They migrate into inflamed tissues and release pro-inflammatory mediators by degranulation upon activation of cell surface receptors such as the high-affinity IgE receptor (FcεRI), the prostaglandin E 2 (PGE 2 ) receptor or the receptor for stem cell factor, KIT. In human and mouse mast cells, stimulation of these receptors results in the rapid PI3K-dependent activation of mTORC1 and mTORC2 (FIG. 4c) . Activation of mTORC1 is required for human and mouse mast cell survival and for the expression of IL-8 and TNF after FcεRI stimulation 145, 148 . mTORC2 activity also contributes to PGE 2 -mediated chemotaxis, CCL2 expression and ROS production 146 . However, constitutive activation of mTORC1 caused by loss of Tsc1 is detrimental and increases mouse mast cell apoptosis by enhancing mitochondrial ROS production and expression of p53, which reduces the expression of the anti-apoptotic molecule B cell lymphoma 2 (BCL-2) . mTORC2 activates RAS homologue (RHO) GTPases and AKT2 to regulate F-actin assembly at the leading edge. mTORC2 is also critical for tail retraction by phosphorylating protein kinase CβII (PKCβII). PKCβII then activates adenylyl cyclase 9 (AC9), which converts ATP into cyclic AMP (cAMP) to activate RHOA. RHOA induces myosin II phosphorylation and tail retraction. b | mTORC1 controls the translation of preformed mRNA encoding cyclooxygenase 2 (COX2) in lipopolysaccharide (LPS)-or formyl-methionyl-leucylphenylalanine (fMLP)-activated neutrophils to induce the expression of prostaglandins that promote vasodilation. Soluble interleukin-6 receptor-α (sIL-6Rα) is synthesized downstream of mTORC1. sIL-6Rα translocates to endothelial cells and induces a switch from neutrophil to mononuclear leukocyte recruitment to initiate the resolution of inflammation. mTORC1 promotes LPS-mediated neutrophil extracellular trap (NET) formation through translational control of hypoxia-inducible factor 1α (HIF1α) expression. Activation of mTORC1 can also negatively influence fMLP-stimulated NET formation by inhibiting autophagy, although the mechanisms involved remain unknown (indicated by ?). c | Activation of the high-affinity receptor for IgE (FcεRI), prostaglandin E 2 receptor (PGE 2 R) or KIT results in rapid phosphatidylinositol 3-kinase (PI3K)-dependent activation of mTORC1 and mTORC2 in mast cells. mTORC1 is required for mast cell survival and for the expression of IL-6, IL-8 and tumour necrosis factor (TNF) following FcεRI stimulation. However, constitutive activation of mTORC1 owing to loss of tuberous sclerosis 1 (TSC1) is detrimental and increases apoptosis by enhancing the expression of p53, which reduces the expression of B cell lymphoma 2 (BCL-2). mTORC2 promotes PGE 2 -mediated chemotaxis, CC-chemokine ligand 2 (CCL2) expression and reactive oxygen species (ROS) production. TSC1 promotes mast cell degranulation and histamine production independently of mTORC1. Rapamycin-insensitive companion of mTOR (RICTOR) contributes to FcεRI-induced degranulation independent of mTORC2 (dashed arrows). d | IL-15 activates mTORC1 through PI3K, 3-phosphoinositide-dependent protein kinase 1 (PDPK1) and AKT in natural killer (NK) cells. mTORC1 promotes NK cell proliferation and the acquisition of cytotoxicity through the induction of interferon-γ (IFNγ) and granzyme B production. mTORC1-mediated cytotoxicity requires metabolic reprogramming and enhanced glycolysis.
and histamine production in vitro and in vivo 148 . Interestingly, rapamycin is incapable of restoring the impaired degranulation in TSC1-deficient cells, suggesting an mTORC1-independent mechanism. Surprisingly, downregulation of RICTOR expression increases FcεRI-induced degranulation independently of mTORC2 (REF. 149 (FIG. 4d) . This mTORC1 activation is important for efficient mouse NK cell proliferation and the acquisition of cytotoxicity through the production of IFNγ and granzyme B 16, 47, 151 . Rapamycin or genetic deletion of mTOR in NK cells blocks their proliferation and expression of IFNγ and granzyme B, and results in elevated viral burdens upon mouse cytomegalovirus infection 16, 151 . Rapamycin inhibits NK cell proliferation and cytotoxicity in humans, and there is a significant decrease in NK cells in rapamycin-treated transplant recipients 153 . Upon activation, mouse NK cells undergo mTORC1-dependent metabolic reprogramming to upregulate glucose uptake and increase aerobic glycolysis 47 . Directly limiting the rate of glycolysis is sufficient to block the cytotoxic activity of NK cells 47 , indicating that NK cells are exquisitely dependent on mTORC1-regulated glucose import and use. The finding that rapamycin inhibits IL-5 and IL-13 production by IL-33-stimulated group 2 ILCs (ILC2s) suggests a broader role of mTOR in the metabolic regulation of ILC functions 154 .
Summary and future directions
The past few years have provided us with a wealth of information about how the mTOR signalling pathway operates in innate immunity. A central paradigm emerges suggesting that activation of innate immune cells via pattern recognition receptors or growth factor receptors triggers the mTOR signalling pathway, which further integrates the environmental and intracellular nutritional and energy status to guide and shape the effector response. This occurs partially via the reconfiguration of cellular metabolism to provide energy and building blocks for the subsequent immune response of the cell. In addition, mTOR modulates central transcription pathways, such as the NF-κB, STAT3, HIF1α and PPARγ pathways, in a cell-type-specific manner. Although mTOR broadly supports many innate immune functions, a properly timed activation pattern of the mTOR network seems to be equally essential and might explain some of the unexpected observations in cells in which mTORC1 is constitutively activated. Moreover, the realization that the environmental nutritional status is sensed by mTOR will have important implications for the design and interpretation of in vitro cell culture experiments. Our current knowledge is just the starting point for further studies that will shed new light on the impact of the mTOR signalling network on distinct effector responses. Which extracellular nutrients and metabolites are specifically sensed by mTOR in the context of inflamma tory responses? How does mTOR regulate the metabolic system in the context of macrophage polarization and other effector responses? Does the mTOR network control macrophage proliferation and is this an important determinant for tissue homeostasis? Lysosomes seem to be central intracellular compartments in which mTOR signalling occurs. As lysosomes are essential for phago cytosing cells and the mTORC1-regulated lysosomal transcription factor TFEB is a regulator of host defence 155 , the intimate relationship between mTORC1 and lysosome function in the context of bacterial infections and athero sclerosis needs to be further explored. How important is the mTOR-mediated regulation of protein translation for the currently underappreciated role of total protein synthesis during immune effector responses? Answering these and other questions will provide exciting new insights into the regulation of innate immune responses by mTORC1 and mTORC2 and will reveal new opportunities for therapeutic approaches.
